Abstract: Disclosed herein is a compound according to one of the formulas wherein R is Additionally, pharmaceutically acceptable salt thereof, and methods of treating disease, medicaments, and compositions related thereto, are further elaborated herein.
Type:
Grant
Filed:
January 13, 2009
Date of Patent:
June 21, 2011
Assignee:
Allergan, Inc.
Inventors:
Brent A. Johnson, David W.. Old, Yariv Donde, Robert M. Burk
Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein Y, A, B, and J are as described. Methods, compositions, and medicaments related thereto are also disclosed.
Abstract: Compounds having a structure are disclosed herein. Compositions, methods, and medicaments related to the therapeutic use of these compounds are also disclosed.
Type:
Grant
Filed:
April 21, 2009
Date of Patent:
June 21, 2011
Assignee:
Allergan, Inc.
Inventors:
Yariv Donde, Jeremiah H. Nguyen, Mark Holoboski, Mari Posner, Robert M. Burk
Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein J1, J2, B, Y, A and D are as described. Methods, compositions, and medicaments related thereto are also disclosed.
Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein Y, A, R1, R2, Z, and G are as described. Methods, compositions, and medicaments related thereto are also disclosed.
Type:
Grant
Filed:
March 17, 2009
Date of Patent:
June 14, 2011
Assignee:
Allergan, Inc.
Inventors:
Mark Holoboski, Robert M. Burk, Mari Posner
Abstract: A compound comprising or a pharmaceutically acceptable salt, prodrug, or a metabolite thereof is disclosed herein. Y, A, and B are as described herein. Methods, compositions, and medicaments related to these compounds are also disclosed.
Abstract: Disclosed herein is a compound according to one of the formulas or a pharmaceutically acceptable salt thereof, medicaments for the treatment of glaucoma or ocular hypertension and compositions related thereto, as further elaborated herein.
Type:
Grant
Filed:
January 30, 2008
Date of Patent:
June 14, 2011
Assignee:
Allergan, Inc.
Inventors:
Brent A. Johnson, David W. Old, Yariv Donde, Robert M. Burk
Abstract: Disclosed herein are compounds useful in treating glaucoma, inflammatory bowel disease, the stimulation of hair growth, and the stimulation of the conversion of vellus hair to terminal hair. The compounds themselves are herein.
Abstract: A compound having the formula or a pharmaceutically acceptable salt or a prodrug thereof is disclosed herein. Y, A, U, and B are as described herein. Methods, compositions, and medicaments related to these compounds are also disclosed.
Abstract: According to the invention there is provided a compound the formula I; wherein A, X, B, R1, R2, R3 and R4 are as defined in the specification.
Abstract: The present invention provides wherein R1 is selected from the group consisting of C1-C10 alkoxy, OH and NR4R5; R2 is selected from the group consisting of C1-C10 alkyl and (CH2)nOH; R3 is selected from the group consisting of C1-C10 alkyl, heteroaryl, e.g. thienyl, furanyl and pyridyl, phenyl, mono, -di-, tri-substituted phenyl and heteroaryl; R4 and R5 are independently selected from the group consisting of H, C1-C10 alkyl, C1-C10 alkyl hydroxyl; m is 0 or an integer from 1 to 3 and n is an integer of from 1 to 4. These compounds are useful in lowering intraocular pressure and/or treating glaucoma or providing neuroprotection to the eye of a human patient.
Abstract: The present invention provides a method of making an imidazole 2-thione which comprises the step(s) of reducing a thiohydantoin to said imidazole-2-thione.
Type:
Grant
Filed:
August 29, 2006
Date of Patent:
April 5, 2011
Assignee:
Allergan, Inc.
Inventors:
Michael E. Garst, Lloyd J. Dolby, Shervin Esfandiari, Alfred A. Avey, Jr., Vivian Rose MacKenzie, Charles David Muchmore
Abstract: A compound comprising or a pharmaceutically acceptable salt or a prodrug thereof, having the groups described in detail herein is disclosed. Also disclosed herein are compounds comprising or derivatives thereof, or pharmaceutically acceptable salts, tetrazoles, or prodrugs of compounds of the structure or derivatives thereof, said derivatives being described in detail herein. Also disclosed herein are methods of treating diseases or conditions, including glaucoma and elevated intraocular pressure. Compositions and methods of manufacturing medicaments related thereto are also disclosed.
Type:
Grant
Filed:
August 10, 2004
Date of Patent:
March 15, 2011
Assignee:
Allergan, Inc.
Inventors:
Yariv Donde, Robert M. Burk, Michael E. Garst
Abstract: Disclosed herein is a compound having a structure or a pharmaceutically acceptable salt thereof, or a prodrug thereof. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.
Type:
Grant
Filed:
June 2, 2009
Date of Patent:
March 1, 2011
Assignee:
Allergan, Inc.
Inventors:
Robert M. Burk, David W. Old, Todd S. Gac
Abstract: Methods are provided directed to administering a therapeutically effective amount of a prostaglandin EP4 agonist component to a mammal afflicted with or prone to afflicted with a disease or condition selected from an esophageal ulcer, alcohol gastropathy, a duodenal ulcer, non-steroidal anti-inflammatory drug-induced gastropathy, non-steroidal anti-inflammatory drug-induced enteropathy and intestinal ischemia. Such administration results in treating the disease or condition.
Type:
Grant
Filed:
November 30, 2005
Date of Patent:
February 22, 2011
Assignee:
Allergan, Inc.
Inventors:
Guang-Liang Jiang, Wha Bin Im, Larry A. Wheeler
Abstract: The present invention provides a process for the preparation of imidazoles by reacting a cyano compound with a silylalkylisocyanide compound. Such imidazoles are useful pharmacologically-active compounds and/or intermediates for the preparation of pharmacologically-active compounds.
Type:
Grant
Filed:
May 4, 2007
Date of Patent:
February 1, 2011
Assignee:
Allergan, Inc.
Inventors:
Lloyd J. Dolby, Shervin Esfandiari, Michael E. Garst
Abstract: A method is disclosed herein comprising administering a compound and a second drug to an eye of a mammal for the treatment of glaucoma or the reduction of intraocular pressure, said compound represented by the general formula I; wherein A, B, D, X, Y, Z, R1, R3 and R4 are as defined in the specification.
Type:
Grant
Filed:
May 16, 2005
Date of Patent:
January 18, 2011
Assignee:
Allergan, Inc.
Inventors:
Robert M. Burk, Mark Holoboski, Scott M. Whitcup, Wha-Bin Im
Abstract: The present invention provides prostamide receptor antagonist compounds that may be represented by the general formula I wherein A, R1, R2, R3, R4 and R6 are as defined in the specification.
Type:
Grant
Filed:
October 9, 2007
Date of Patent:
January 11, 2011
Assignee:
Allergan, Inc.
Inventors:
David F. Woodward, Jenny W. Wang, Clive L. Cornell, Hans G. Fliri, Jose L. Martos, Simon N. Pettit